Compare BX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BX | TOVX |
|---|---|---|
| Founded | 1985 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.1B | 6.4M |
| IPO Year | 2007 | 2012 |
| Metric | BX | TOVX |
|---|---|---|
| Price | $115.91 | $0.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 2 |
| Target Price | ★ $139.04 | $2.50 |
| AVG Volume (30 Days) | ★ 4.5M | 1.1M |
| Earning Date | 10-22-2026 | 11-12-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | 6.91 | ★ 89.07 |
| EPS | ★ 3.19 | N/A |
| Revenue | ★ $14,450,265,000.00 | N/A |
| Revenue This Year | $4.03 | N/A |
| Revenue Next Year | $24.39 | N/A |
| P/E Ratio | $36.37 | ★ N/A |
| Revenue Growth | ★ 9.22 | N/A |
| 52 Week Low | $101.73 | $0.13 |
| 52 Week High | $165.14 | $0.49 |
| Indicator | BX | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 27.38 |
| Support Level | $105.57 | N/A |
| Resistance Level | $130.00 | $0.25 |
| Average True Range (ATR) | 3.85 | 0.02 |
| MACD | -0.47 | -0.00 |
| Stochastic Oscillator | 12.62 | 1.22 |
Blackstone is the world's largest alternative-asset manager with $1.346 trillion in total assets under management, including $961.6 billion in fee-earning assets under management, at the end of June 2026. The company operates with scale in each of its major product lines: private equity (28% of fee-earning AUM and 35% of base management fees), real estate/real assets (29% and 32%), credit and insurance (33% and 25%), and other alternatives (10% and 8%). While the firm primarily serves institutional investors (84% of AUM), it also caters to clients in the high-net-worth channel (16%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.